Drug Trial Radar · NCT00107978
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Last checked: Nov 20, 2026Latest source record: Jan 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,035
Actual
Start
Feb 2005
Primary completion
May 2006
Study completion May 2006
Sponsor
- Lead sponsor
- Cumberland PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study 0018 (NCT00107978) compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
Conditions
- Staphylococcal Skin Infection
Interventions
TelavancinDrug
Telavancin 10 mg/kg/day, IV for up to 14 days.
VancomycinDrug
Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical ResponseTime frame: 7 to 14 days after the last antibiotic dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Louisiana State University Health Sciences Center, Dept of Med/ER Med
New Orleans, Louisiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.